Enhanced cytotoxicity of 5-fluorouracil combined with [6RS]leucovorin and recombinant human interferon-alpha 2a in colon carcinoma cells.
Houghton
J A
JA
Department of Biochemical and Clinical Pharmacology, St. Jude Children's Research Hospital, Memphis, TN 38101.
Adkins
D A
DA
Houghton
P J
PJ
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002470:Cell Survival / Q000187:drug effects; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004357:Drug Synergism; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D002955:Leucovorin / Q000627:therapeutic use; D011994:Recombinant Proteins; D013237:Stereoisomerism; D014407:Tumor Cells, Cultured
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D002955:Leucovorin; D005472:Fluorouracil